Roadshow
AmCAD-UO
AmCAD-UO is the world first CE marked/FDA 510K cleared solution for upper airway exam to detect Obstructive Sleep Apnea (OSA) from patients who are awake. With laser-guided positioning and automated ultrasound scanning device, AmCAD-UO can precisely scan upper airway and analyze the gap between normal breathing and Müller Maneuver. The system standardizes ultrasound transducer scanning to make the assessment more consistent and avoid high operator dependent variations. This allows doctors to evaluate the cause of OSA more quickly in just 10 minutes and offer quantitative visual assessment for moderate/severe OSA patients.
AmCAD-UO offers 10-minute detection for obstructive sleep apnea on awake patients, helping doctors to evaluate the root cause of sleep apnea and offer assessment for moderate/severe OSA patients. With laser-guided positioning, AmCAD-UO can precisely scan upper airway and analyze the gap between normal breathing and Müller Maneuver models. AmCAD-UO system standardizes ultrasound transducer scanning to reduce intra-observer variations and make the assessment consistent.
*AmCAD-UO has 510(k) clearance(K180867) and CE mark(NB1639).
- Established 2018
- Company AmCad BioMed Corporation.
- Telephone +886-2-2713-6227
- Address Fl.5-2, No. 167, Fu Hsing N. RD. Taipei 105, Taiwan
AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in March of 2015 (Ticker: 4188). AmCad is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. Moreover, AmCad is committed to developing unique products that assist medical professionals in making more accurate early diagnoses. By integrating AI with innovative hardware solutions, we aim to solve long-standing unmet medical needs. We are bolstering clinicians’ expertise with AI-driven technology. Our patented algorithms provide medical professionals detailed quantification and visualization of sonographic characteristics.
AmCad has successfully obtained numerous FDA 510(k) Clearances and CE Mark certifications for four products. AmCad's product lines include AmCAD-UT® (FDA, CE Mark, TFDA and CFDA, for thyroid cancer analysis), AmCAD-UO (FDA and CE Mark for obstructive sleep apnea detection), AmCAD-US (FDA and CE Mark for backscattered signals analysis), AmCAD-UV (FDA and CE Mark for classifying pulsatile signals and noise), and AmCAD-CA (Cytopathology analysis). The state-of-the-art pipeline aims for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis and obstructive sleep apnea.